| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA513: Obinutuzumab for untreated advanced follicular lymphoma |
|
Medicine details |
|
| Medicine name | obinutuzumab (Gazyvaro®) |
| Formulation | concentrate for solution for infusion |
| Reference number | 2348 |
| Indication | In combination with chemotherapy, followed by Gazyvaro maintenance therapy in patients achieving a response, for the treatment of patients with previously untreated advanced follicular lymphoma |
| Company | Roche Products Ltd |
| BNF chapter | Malignant disease & immunosuppression |
| Assessment type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 09/08/2017 |
| NICE guidance | TA513: Obinutuzumab for untreated advanced follicular lymphoma |